Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for agitation in Alzheimer's disease
NCT00097916Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Sep 2004
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of memantine in Alzheimer's disease (AD), sponsored by Forest Laboratories. Primary endpoint: Neuropsychiatric Inventory. Started Sep 2004; status: completed.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00097916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097916.